Uvax-2129, a Recombinant Protein Nanoparticle Vaccine, Uvax Bio’s Answer to COVID-19, Shows Great Promise Against Variants of Concern

Uvax-2129 is one of Uvax Bio’s pipeline of vaccine products that are produced using the patented single component self-assembling protein nanoparticle (1c-SApNP^®) antigen design and manufacturing technology. The 1c-SApNP^® technology licensed from Scripps Research is being studied for other candidate vaccine designs, including scale-up of production, for HIV, RSV, HCV, and Ebola virus. Uvax-2129 phase I clinical trial is scheduled for the first half of 2022, while company’s HIV-1 candidate vaccine is also scheduled for its phase I clinical trial in mid-2022.

In mouse studies, Prof. Zhu’s team found, Uvax-2129 elicits immune responses that powerfully neutralize the original Wuhan strain of COVID-19, and all the other major variants of concern including the fast-spreading delta variant with the same potency. They also examined the cellular roots of the immunity induced by Uvax-2129 and observed had much longer and stronger engagement with the immune cells that give rise to long-term immunity when compared with the approach using single-spike protein as vaccines from other technologies.

“Uvax Bio is working with CMO partners on GMP production and release of Uvax-2129 for its clinical phase I trial” commented Cheryl Keech, M.D., Ph.D., Acting Chief Medical Officer of Uvax Bio; “This published study suggests that this vaccine platform has the potential to be broadly immunogenic against SARS-CoV2 variants of concern and we look forward to initiating our phase 1 trial this next year to test Uvax-2129 in a booster setting.”

About Uvax Bio:

Uvax Bio is a privately held biotechnology company focused on the development of protein nanoparticle vaccines for infectious diseases. For more information visit www.uvaxbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211103006353/en/